Mesothelial‐to‐mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer
Ángela Rynne‐Vidal(Centro de Biología Molecular Severo Ochoa), Manuel López‐Cabrera(Consejo Superior de Investigaciones Científicas), Ignacio Cristóbal García(Hospital La Luz), María Luisa Pérez‐Lozano(Inserm), Carmen Bárcena(Universidad Complutense de Madrid), José A. Jiménez‐Heffernan(Hospital Universitario de La Princesa), Concepción Fernández‐Chacón(Hospital La Luz), Lucía Cremades‐Jimeno(Centro de Biología Molecular Severo Ochoa), Tsz Lun Yeung(The University of Texas MD Anderson Cancer Center), Pilar Sandoval(Consejo Superior de Investigaciones Científicas), Chi Lam Au‐Yeung(The University of Texas MD Anderson Cancer Center), Samuel C. Mok(The University of Texas MD Anderson Cancer Center)
Cited by 114
Related Papers
Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1
|Nature Communications|2016|785
Carcinoma‐associated fibroblasts derive from mesothelial cells via mesothelial‐to‐mesenchymal transition in peritoneal metastasis
|The Journal of Pathology|2013|183
Hypoxia Enhances Lysophosphatidic Acid Responsiveness in Ovarian Cancer Cells and Lysophosphatidic Acid Induces Ovarian Tumor Metastasis <i>In vivo</i>
|Cancer Research|2006|160
Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential
|Nature Communications|2014|130